ASX:IMC Immuron (IMC) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free IMC Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume175,856 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield4.51%Price TargetN/A Stock AnalysisStock Analysis Get Immuron alerts: Email Address Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About ImmuronImmuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers' diarrhea in the United States, and Travelers' Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.Read More Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide IMC Stock News HeadlinesJanuary 15, 2022 | marketwatch.comImmuron Receives European Patent on Drug Composition to Treat Travelers' DiarrheaJanuary 13, 2022 | msn.comWhy the Immuron (ASX:IMC) share price rocketed another 17% todayMay 9, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.January 12, 2022 | morningstar.comTrouble for stocks Watch out for stock headwinds and recessionary pressures, warns bond king Jeffrey GundlachJanuary 12, 2022 | morningstar.comWatch out for stock headwinds and recessionary pressures, warns bond king Jeffrey GundlachJanuary 12, 2022 | morningstar.comImmuron stock rockets after funding by U.S. DoD of new research agreementJanuary 12, 2022 | finance.yahoo.comImmuron Receives A$6.2 Million Award from U.S. DoD to Clinically Evaluate a Military Strength Dosing Regimen for TravelanJanuary 11, 2022 | msn.comHere’s why the Immuron (ASX:IMC) share price is rocketing 31% todayMay 9, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.November 15, 2021 | finance.yahoo.comUS DoD Uniformed Services University Travelers’ Diarrhea Clinical UpdateNovember 6, 2021 | afr.comImmuron LimitedOctober 8, 2021 | finance.yahoo.comImmuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19October 7, 2021 | msn.comImmuron (ASX:IMC) share price surges 11% on COVID-19 treatment dataSeptember 25, 2021 | ca.finance.yahoo.comBiQ Made It Into G2’s High Performer List For Leading SEO Software On The Market For The Second TimeSeptember 25, 2021 | yahoo.comDeWine offers $100,000 scholarships to encourage vaccinationsSeptember 24, 2021 | finance.yahoo.comCompanies Like Immuron (ASX:IMC) Are In A Position To Invest In GrowthSee More Headlines Receive IMC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immuron and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:IMC CUSIPN/A CIKN/A Webwww.immuron.com.au Phone61 3 9824 5254FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,880,000.00 Net Margins-108.52% Pretax MarginN/A Return on Equity-20.01% Return on Assets-9.87% Debt Debt-to-Equity Ratio0.97 Current Ratio8.52 Quick Ratio15.15 Sales & Book Value Annual Sales$3.58 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.15 Book ValueA$0.08 per share Price / BookN/AMiscellaneous Outstanding Shares227,800,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.06 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Steven George Lydeamore CPA (Age 56)M.B.A., Chief Executive Officer Comp: $463.77kDr. Jerry Kanellos Ph.D. (Age 63)Chief Operating Officer Comp: $287.83kMr. Flavio Palumbo (Age 50)Chief Commercial Officer Comp: $289.93kMr. Phillip Allen Hains BBus(Acc) (Age 65)C.A., M.B.A., CFO & Company Secretary Mr. David LyonHead of MarketingKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersDaniel PollockSold 200,000 sharesTotal: $24,000.00 ($0.12/share)Daniel PollockSold 200,000 sharesTotal: $31,400.00 ($0.16/share)Paul BrennanSold 1,000,000 sharesTotal: $76,000.00 ($0.08/share) This page (ASX:IMC) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersUrgent Nvidia WarningAltimetryObama’s Forever Term [exposed]Porter & Company348 million Americans lives to END as we know it?The Oxford Club“Crash Insurance” For Your RetirementUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuron Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.